NO2970332T3 - - Google Patents

Info

Publication number
NO2970332T3
NO2970332T3 NO14716910A NO14716910A NO2970332T3 NO 2970332 T3 NO2970332 T3 NO 2970332T3 NO 14716910 A NO14716910 A NO 14716910A NO 14716910 A NO14716910 A NO 14716910A NO 2970332 T3 NO2970332 T3 NO 2970332T3
Authority
NO
Norway
Application number
NO14716910A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48013903&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2970332(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2970332T3 publication Critical patent/NO2970332T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO14716910A 2013-03-15 2014-03-14 NO2970332T3 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13382089 2013-03-15
PCT/GB2014/050825 WO2014140644A1 (en) 2013-03-15 2014-03-14 Chemical entities
EP14716910.6A EP2970332B1 (en) 2013-03-15 2014-03-14 Chemical entities

Publications (1)

Publication Number Publication Date
NO2970332T3 true NO2970332T3 (sr) 2018-07-28

Family

ID=48013903

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14716910A NO2970332T3 (sr) 2013-03-15 2014-03-14

Country Status (32)

Country Link
US (1) US9453031B2 (sr)
EP (1) EP2970332B1 (sr)
JP (1) JP6379115B2 (sr)
KR (1) KR102206318B1 (sr)
CN (1) CN105051047B (sr)
AR (1) AR095443A1 (sr)
AU (1) AU2014229735B2 (sr)
BR (1) BR112015023060B1 (sr)
CA (1) CA2904768C (sr)
CL (1) CL2015002591A1 (sr)
CY (1) CY1120619T1 (sr)
DK (1) DK2970332T3 (sr)
EA (1) EA029771B1 (sr)
ES (1) ES2670674T3 (sr)
HK (1) HK1215021A1 (sr)
HR (1) HRP20180839T1 (sr)
HU (1) HUE037685T2 (sr)
IL (1) IL240708B (sr)
LT (1) LT2970332T (sr)
MX (1) MX368056B (sr)
NO (1) NO2970332T3 (sr)
NZ (1) NZ711038A (sr)
PE (1) PE20152007A1 (sr)
PH (1) PH12015502159B1 (sr)
PL (1) PL2970332T3 (sr)
PT (1) PT2970332T (sr)
RS (1) RS57216B1 (sr)
SG (1) SG11201507555PA (sr)
SI (1) SI2970332T1 (sr)
TW (1) TWI557131B (sr)
UA (1) UA118261C2 (sr)
WO (1) WO2014140644A1 (sr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2897200C (en) 2013-01-14 2021-07-06 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
LT2945939T (lt) 2013-01-15 2020-07-27 Incyte Holdings Corporation Triazolkarboksamidai ir piridinkarboksamido junginiai, naudotini kaip pim kinazės inhibitoriai
TW201605866A (zh) 2013-08-23 2016-02-16 英塞特公司 可用作pim激酶抑制劑之呋喃并-及噻吩并-吡啶甲醯胺化合物
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016112374A2 (en) * 2015-01-09 2016-07-14 The General Hospital Corporation Treating cancer using inhibitors of ataxia-telangiectasia mutated and rad3-related (atr)
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
WO2017202748A1 (en) * 2016-05-24 2017-11-30 Merck Patent Gmbh Tricyclic heterocylic derivatives
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
PL3753937T3 (pl) 2018-02-07 2024-04-02 Wuxi Biocity Biopharmaceutics Co., Ltd. Inhibitor ATR i jego zastosowanie
WO2020094084A1 (zh) * 2018-11-07 2020-05-14 南京明德新药研发有限公司 作为ret抑制剂的三并环衍生物
CN113004303A (zh) * 2019-12-18 2021-06-22 江苏恒瑞医药股份有限公司 嘧啶并噁嗪类三环衍生物、其制备方法及其在医药上的应用
WO2021143821A1 (zh) * 2020-01-17 2021-07-22 江苏恒瑞医药股份有限公司 稠合杂芳基类衍生物、其制备方法及其在医药上的应用
KR20230088709A (ko) 2020-10-16 2023-06-20 상하이 드 노보 파마테크 컴퍼니 리미티드 트리헤테로사이클릭 유도체, 이의 약학적 조성물 및 용도
CN115466258A (zh) * 2021-06-11 2022-12-13 成都苑东生物制药股份有限公司 Atr抑制剂及其用途
CN115286645A (zh) * 2022-08-16 2022-11-04 南京雷正医药科技有限公司 三环杂环衍生物及其药物组合物和用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
WO1993014080A1 (en) * 1992-01-15 1993-07-22 E.I. Du Pont De Nemours And Company Bridged heterocyclic fungicides
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
NZ337750A (en) 1997-02-12 2001-08-31 Univ Michigan Protein markers for lung cancer and use thereof
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
ES2351699T3 (es) 1999-02-10 2011-02-09 Astrazeneca Ab Derivados de quinazolina como inhibidores de la angiogénesis e intermedios de los mismos.
UA72946C2 (uk) 1999-11-05 2005-05-16 Астразенека Аб Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf)
NZ520640A (en) 2000-02-15 2005-04-29 Upjohn Co Pyrrole substituted 2-indolinone protein kinase inhibitors
EP1289952A1 (en) 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
CA2410562A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
EP1301497A1 (en) 2000-07-07 2003-04-16 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
US8735411B2 (en) * 2006-10-02 2014-05-27 Abbvie Inc. Macrocyclic benzofused pyrimidine derivatives
WO2008052733A1 (en) * 2006-10-30 2008-05-08 Novartis Ag Imidazopyridazines as pi3k lipid kinase inhibitors
MX2009012066A (es) * 2007-05-09 2009-11-19 Novartis Ag Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k.
ES2534326T3 (es) * 2009-08-20 2015-04-21 Karus Therapeutics Limited Compuestos tricíclicos heterocíclicos como inhibidores de la fosfoinositida 3-cinasa
CN102020657A (zh) * 2009-09-11 2011-04-20 上海艾力斯医药科技有限公司 稠合杂芳基衍生物、制备方法及其应用
US8623869B2 (en) * 2010-06-23 2014-01-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
CN105859735B (zh) * 2010-12-16 2018-03-09 霍夫曼-拉罗奇有限公司 三环pi3k抑制剂化合物和使用方法

Also Published As

Publication number Publication date
JP6379115B2 (ja) 2018-08-22
PL2970332T3 (pl) 2018-08-31
EP2970332A1 (en) 2016-01-20
TWI557131B (zh) 2016-11-11
TW201446772A (zh) 2014-12-16
UA118261C2 (uk) 2018-12-26
KR102206318B1 (ko) 2021-01-25
PT2970332T (pt) 2018-05-25
HRP20180839T1 (hr) 2018-06-29
SG11201507555PA (en) 2015-10-29
JP2016510803A (ja) 2016-04-11
AR095443A1 (es) 2015-10-14
PH12015502159A1 (en) 2016-01-25
CA2904768A1 (en) 2014-09-18
ES2670674T3 (es) 2018-05-31
EP2970332B1 (en) 2018-02-28
NZ711038A (en) 2020-02-28
US9453031B2 (en) 2016-09-27
SI2970332T1 (en) 2018-06-29
DK2970332T3 (en) 2018-05-22
CA2904768C (en) 2021-07-27
AU2014229735B2 (en) 2018-08-09
MX368056B (es) 2019-09-18
AU2014229735A1 (en) 2015-09-03
EA201591781A1 (ru) 2016-02-29
BR112015023060B1 (pt) 2022-07-05
PH12015502159B1 (en) 2016-01-25
CL2015002591A1 (es) 2016-02-05
EA029771B1 (ru) 2018-05-31
LT2970332T (lt) 2018-06-11
KR20150129741A (ko) 2015-11-20
BR112015023060A2 (pt) 2017-07-18
PE20152007A1 (es) 2016-02-04
IL240708B (en) 2019-08-29
HK1215021A1 (zh) 2016-08-12
CY1120619T1 (el) 2019-12-11
CN105051047A (zh) 2015-11-11
IL240708A0 (en) 2015-10-29
WO2014140644A1 (en) 2014-09-18
MX2015011549A (es) 2016-05-31
HUE037685T2 (hu) 2018-09-28
US20160024112A1 (en) 2016-01-28
CN105051047B (zh) 2017-12-15
RS57216B1 (sr) 2018-07-31

Similar Documents

Publication Publication Date Title
BR112015007533A2 (sr)
BR102016010778A2 (sr)
BR112016005228A2 (sr)
BR112016000858A2 (sr)
BR112014018502A2 (sr)
BR112014017739A2 (sr)
BR112014019326A2 (sr)
BR112016001700A2 (sr)
BR112016007916A2 (sr)
BR112014020341A2 (sr)
BR112014018480A2 (sr)
BR112014017855A2 (sr)
BR112014017765A2 (sr)
BR112014021878A2 (sr)
NO2970332T3 (sr)
BR112014018468A2 (sr)
BR112014018207A2 (sr)
BR112014017901A2 (sr)
BR112014019204A2 (sr)
BR112015015948A2 (sr)
BR112014017722A2 (sr)
BR112014018578A2 (sr)
BR112014018483A2 (sr)
BR112014017794A2 (sr)
BR112014017653A2 (sr)